$DRMA News

Why Is Dermata Therapeutics Stock Gaining Thursday?

Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment

Dermata Therapeutics Announces Over 71% Of Patients Had Overall Skin Improvements At Day 29 In Its Cosmetic Clinical Trial Of Tome Foundational Treatment

Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment

Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch

Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Stock Surges 27% Pre-Market: Why is it Moving?

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment

Dermata Therapeutics (NASDAQ:DRMA) Q1 2026 Earnings: Narrowing Losses and Strategic Pivot to DTC Skincare

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026

Dermata Therapeutics Q1 EPS $(0.48) Beats $(0.53) Estimate

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025

Dermata Therapeutics Q4 EPS $(1.52) Beats $(1.54) Estimate

Dermata Shares Rise After USPTO Issues Patent Notice Of Allowance

Dermata Therapeutics shares are trading higher after the U.S. Patent and Trademark Office issued the company a notice of allowance for a U.S. patent titled "COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS."

Dermata Therapeutics shares are trading higher after the U.S. Patent and Trademark Office issued the company a notice of allowance for a U.S. patent titled "COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS."

Dermata Therapeutics shares are trading higher after the U.S. Patent and Trademark Office issued the company a notice of allowance for a U.S. patent titled "COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS"

UPDATE: Dermata Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS"